We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Phaxiam Therapeutics | LSE:0QSS | London | Ordinary Share | FR001400K4B1 | PHAXIAM THERAPEUTICS ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 71.025 | 6.925 | 7.28 | 10 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.33M | -23.49M | - | N/A | 0 |
PRESS RELEASE
PHAXIAM Therapeutics announces a reverse share split of its shares
Lyon (France) and Cambridge (MA, US), July 27th, 2023 - PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM) (the "Company"), today announces the implementation of the reverse share split of the shares composing the Company's share capital, by decision of the Chief Executive Officer on July 27th, 2023, following the sub-delegation granted by the Board of Directors on June 23rd, 2023, taken in accordance with the twenty-third extraordinary resolution of the General Shareholders' Meeting of June 23rd, 2023.
REVERSE SHARE SPLIT OF THE COMPANY'S SHARES
The reverse share split will result in the exchange of ten (10) existing shares with a par value of ten-euro cents (€0.10) (the "Existing Shares") for one (1) new share with a par value of one euro (€1) (a "New Share").
This reverse share split will have no impact on the Company's share capital and will result in the division of the number of shares outstanding by ten (10).
Terms of the implementation of the reverse share split
All the terms and conditions of the reverse share split were decided by the Chief Executive Officer on July 27th, 2023, pursuant to the sub-delegation granted by the Board of Directors on June 23rd, 2023, and are detailed in the reverse share split notice published in the Bulletin des Annonces Légales Obligatoires (BALO) on July 31st, 2023.
The number of New Shares resulting from the reverse stock split may be adjusted in the event that holders of rights or securities giving access to the share capital exercise them outside the period of suspension of their right to exercise.
The definitive number of New Shares to be issued as a result of the reverse share split will be recorded by the Company's Board of Directors or by the Chief Executive Officer at the end of the reverse share split.
The non-consolidated Existing Shares will be delisted at the end of the exchange period.
The Existing Shares subject to the reverse share split will be admitted to trading on the regulated market of Euronext Paris under ISIN code FR0011471135, until September 15th, 2023, the last day of trading.
The New Shares resulting from the reverse share split will be admitted to trading on the regulated market of Euronext in Paris from September 18th, 2023, the first day of trading, and will be assigned a new ISIN code.
Indicative timetable:
July 31st, 2023 | Publication of the reverse share split notice in the Bulletin des Annonces Légales Obligatoires |
August 16th, 2023 | Start of reverse share split transactions Possibility for shareholders to buy and sell shares in order to obtain a number of shares without fractional rights until September 15th, 2023 |
September 15th, 2023 | Closing of the Exchange Period |
September 15th, 2023 | Last trading day for the Existing Shares |
September 18th, 2023 | Listing of the New Shares |
September 20th, 2023 | Settlement-delivery of the New Shares |
***
About PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma& Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit www.erytech.com
Contacts
PHAXIAMEric SoyerCOO & CFO+33 4 78 74 44 38investors@erytech.com | NewCapMathilde Bohin / Louis-Victor DelouvrierInvestor RelationsArthur Rouillé Media Relations +33 1 44 71 94 94phaxiam@newcap.eu |
Attachment
1 Year Phaxiam Therapeutics Chart |
1 Month Phaxiam Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions